The long and winding road: Adjuvant therapy for early-stage hepatocellular carcinoma

Despite being the first positive phase 3 trial in the adjuvant setting for early-stage hepatocellular carcinoma, the IMbrave050 study raises a number of questions regarding patient selection, endpoint robustness, and the balance between efficacy and acceptable toxicity. 1 Qin S. Chen M. Cheng A.-L. Kaseb A.O. Kudo M. Lee H.C. Yopp A.C. Zhou J. Wang L. Wen X. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 402: 1835-1847 Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar Despite being the first positive phase 3 trial in the adjuvant setting for early-stage hepatocellular carcinoma, the IMbrave050 study raises a number of questions regarding patient selection, endpoint robustness, and the balance between efficacy and acceptable toxicity. 1 Qin S. Chen M. Cheng A.-L. Kaseb A.O. Kudo M. Lee H.C. Yopp A.C. Zhou J. Wang L. Wen X. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023; 402: 1835-1847 Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar